Hyun Hwangbo, Min Yeong Kim, Seon Yeong Ji, So Young Kim, Hyesook Lee, Gi-Young Kim, . . . Yung Hyun Choi. (2020). Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. MDPI AG.
Chicago Style (17th ed.) CitationHyun Hwangbo, et al. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. MDPI AG, 2020.
MLA (9th ed.) CitationHyun Hwangbo, et al. Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro. MDPI AG, 2020.
Warning: These citations may not always be 100% accurate.